Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?","authors":"Rodney J Hicks","doi":"10.2967/jnumed.125.269496","DOIUrl":"https://doi.org/10.2967/jnumed.125.269496","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noninvasive Characterization of Hepatic Lesions by Means of Glypican-3-Directed PET/CT.","authors":"Helen Scholtissek, Nic G Reitsam, Alexander Dierks, Thomas Kröncke, Bruno Märkl, Martin Trepel, Ralph A Bundschuh, Constantin Lapa","doi":"10.2967/jnumed.124.269290","DOIUrl":"https://doi.org/10.2967/jnumed.124.269290","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are FAP Theranostics Really Happening? Will Radiochemistry or Biology Win?","authors":"Rodney J Hicks","doi":"10.2967/jnumed.124.267547","DOIUrl":"10.2967/jnumed.124.267547","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"497-499"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Stabilization to Depletion: Molecular Imaging to Measure Therapeutic Response in ATTR-CA.","authors":"Shilpa Vijayakumar, Sharmila Dorbala","doi":"10.2967/jnumed.124.268035","DOIUrl":"10.2967/jnumed.124.268035","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"500-501"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CCK₂ Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer.","authors":"Oliver Viering, Nadine Holzleitner, Rainer Claus, Adriana Amerein, Niklas Dreher, Johanna S Enke, Alexander Dierks, Christian H Pfob, Malte Kircher, Veronika Felber, Thomas Günther, Constantin Lapa","doi":"10.2967/jnumed.124.269201","DOIUrl":"10.2967/jnumed.124.269201","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"662"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[^99mTc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study.","authors":"Yining Sun, Zhixin Hao, Hannan Gao, Guangjie Yang, Bo Pan, Min Zhu, Yakun Wan, Jiyun Shi, Li Huo, Haojun Chen, Fan Wang","doi":"10.2967/jnumed.124.268564","DOIUrl":"10.2967/jnumed.124.268564","url":null,"abstract":"<p><p>The trophoblast cell-surface antigen 2 (Trop2) is markedly overexpressed in breast cancers, with a particularly high incidence in triple-negative breast cancer. The therapeutic relevance of Trop2 expression is underscored by the approval of an antibody-drug conjugate for triple-negative breast cancer treatment. However, there is no a predictive technique for accurate whole-body mapping of Trop2 expression in patients. In this study, we developed a novel Trop2-specific molecular probe, [^99mTc]Tc-MY6349, and evaluated its safety and feasibility for detecting Trop2 expression in breast cancer using SPECT/CT imaging. <b>Methods:</b> Trop2 expression in different breast cancer cell lines was assessed via immunofluorescence and flow cytometry. The Trop2-specific nanobody MY6349 was site-specifically labeled with ^99mTc via a C-terminal GGGC tag, and its binding affinity to the Trop2 receptor was tested in vitro. The in vivo tumor uptake and distribution of [^99mTc]Tc-MY6349 were examined through SPECT imaging and biodistribution studies. Furthermore, a pilot clinical study of [^99mTc]Tc-MY6349 SPECT/CT was conducted in 8 patients with breast cancer, and the results were compared with [¹⁸F]FDG PET/CT. <b>Results:</b> [^99mTc]Tc-MY6349 achieved a greater than 95% radiochemical purity after purification. In vitro and in vivo experiments demonstrated the binding specificity of [^99mTc]Tc-MY6349 to the Trop2 receptor. In vivo imaging and biodistribution studies revealed a significant correlation between tumor uptake and Trop2 expression levels. In the pilot clinical study, SPECT imaging with [^99mTc]Tc-MY6349 successfully detected Trop2-positive tumors 15 min after tracer injection. Delayed imaging showed reduced uptake in normal organs but sustained retention of [^99mTc]Tc-MY6349 in tumors. Importantly, [^99mTc]Tc-MY6349 SPECT/CT imaging highlighted Trop2 expression heterogeneity and visualized primary and metastatic lesions with a favorable tumor-to-background ratio in breast cancer. <b>Conclusion:</b> [^99mTc]Tc-MY6349 was successfully prepared and exhibited a high binding affinity and Trop2 specificity. The pilot clinical study validated the safety and feasibility of [^99mTc]Tc-MY6349 SPECT/CT for detecting Trop2 expression in vivo in patients with breast cancer. This imaging modality could complement existing methods, aiding in the guidance of Trop2-targeted therapies and advancing personalized treatment while also promoting the application of SPECT/CT nuclear medicine imaging technology.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"543-551"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁷⁶Lu Radiation Dose of Long-Axial Field of View PET Scanners.","authors":"Samaneh Mostafapour, Joyce van Sluis, Adriaan A Lammertsma, Charalampos Tsoumpas","doi":"10.2967/jnumed.124.269187","DOIUrl":"10.2967/jnumed.124.269187","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"663"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The PRIMARY Score: Present and Future.","authors":"Linlin Guo, Guohua Shen","doi":"10.2967/jnumed.124.267898","DOIUrl":"10.2967/jnumed.124.267898","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"663-664"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.","authors":"Tahir Yusufaly, Emilie Roncali, Julia Brosch-Lenz, Carlos Uribe, Abhinav K Jha, Geoffrey Currie, Joyita Dutta, Georges El-Fakhri, Helena McMeekin, Neeta Pandit-Taskar, Jazmin Schwartz, Kuangyu Shi, Lidia Strigari, Habib Zaidi, Babak Saboury, Arman Rahmim","doi":"10.2967/jnumed.124.267927","DOIUrl":"10.2967/jnumed.124.267927","url":null,"abstract":"<p><p>Radiopharmaceutical therapy (RPT), with its targeted delivery of cytotoxic ionizing radiation, demonstrates significant potential for treating a wide spectrum of malignancies, with particularly unique benefits for metastatic disease. There is an opportunity to optimize RPTs and enhance the precision of theranostics by moving beyond a one-size-fits-all approach and using patient-specific image-based dosimetry for personalized treatment planning. Such an approach, however, requires accurate methods and tools for the mathematic modeling and prediction of dose and clinical outcome. To this end, the SNMMI AI-Dosimetry Working Group is promoting the paradigm of computational nuclear oncology: mathematic models and computational tools describing the hierarchy of etiologic mechanisms involved in RPT dose response. This includes radiopharmacokinetics for image-based internal dosimetry and radiobiology for the mapping of dose response to clinical endpoints. The former area originates in pharmacotherapy, whereas the latter originates in radiotherapy. Accordingly, models and methods developed in these predecessor disciplines serve as a foundation on which to develop a repurposed set of tools more appropriate to RPT. Over the long term, this computational nuclear oncology framework also promises to facilitate widespread cross-fertilization of ideas between nuclear medicine and the greater mathematic and computational oncology communities.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"509-515"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.","authors":"Victor Santoro-Fernandes, Brayden Schott, Amy J Weisman, Ojaswita Lokre, Steve Y Cho, Scott B Perlman, Timothy G Perk, Robert Jeraj","doi":"10.2967/jnumed.124.267809","DOIUrl":"10.2967/jnumed.124.267809","url":null,"abstract":"<p><p>Patients with metastatic neuroendocrine tumors (NETs) can present with hundreds of lesions, and each lesion might have a unique response pattern to peptide receptor radiopharmaceutical therapy (PRRT). This response heterogeneity has been observed but is poorly understood. In this work, we perform a quantitative analysis of longitudinal PET/CT scans to comprehensively characterize the NET response to PRRT. <b>Methods:</b> NET patients treated with [¹⁷⁷Lu]Lu-DOTATATE PRRT imaged at baseline, during, and after PRRT with [⁶⁸Ga]Ga-DOTATATE PET/CT were enrolled in this retrospective single-institutional study. A deep-learning model was used to identify and contour regions of nonphysiological elevated tracer uptake (lesion-regions of interest [ROIs]). An automated analysis was performed to identify, contour, and quantify the individual lesion-ROI uptake, match ROI between time points, and categorize each lesion-ROI as disappearing, decreasing (ΔSUV_total < -30%), stable (-30% ≤ ΔSUV_total ≤ 30%), increasing (ΔSUV_total > 30%), or new. A patient was considered to have response heterogeneity if both new or increasing lesion-ROIs and decreasing or disappearing lesion-ROIs were present after therapy. <b>Results:</b> Eighteen patients who received between 2 and 7 [⁶⁸Ga]Ga-DOTATATE PET/CT scans were enrolled. In total, 3,289 lesion-ROIs were contoured in the 67 scans acquired (median of 24 lesion-ROIs per image), and 1,459 lesion-ROI tracks, defined as the path that each unique lesion-ROI follows across all time points, were determined by the ROI tracking method (median of 49 tracks per patient). All patients presented with disease response heterogeneity at the first follow-up scan. All 10 patients with more than 1 follow-up scan showed nonmonotonic change in lesion-ROI uptake. Of 129 tracks containing new lesion-ROIs at the first follow-up, 80 (62%) eventually resolved on final follow-up, whereas only 12% (7/60) of the tracks with lesion-ROIs disappearing at the first follow-up scan returned on final follow-up. <b>Conclusion:</b> To the best of our knowledge, this is the first study to evaluate response comprehensively and quantitatively in terms of individual lesion-ROIs. Response heterogeneity was observed in 100% of the patients, which suggests that comprehensive, lesion-level, response assessment is vital for the accurate understanding of the NET response to PRRT.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"565-571"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}